Introduction
Master of Science (MSc) in Drug Regulatory Affairs and Policy (DRAP) offers a high-quality MSc program designed to train professionals in drug regulatory affairs and policy, which are critical areas for Hong Kong and Greater Bay Area development. A notable highlight in the HKSAR Policy Address 2023 is the establishment of Hong Kong Centre for Medical Products Regulation (CMPR). The HKCMPR will be dedicated to potential restructuring and strengthening of current regulatory and approval regimes for medicine, medical devices and medical technology, in order to accelerate the approving applications and launching for registration of pharmaceutical products to the market. Our program is unique for preparing students to become proficient managers and main practitioners of guidance documents, laws, and regulations for pharmaceutical companies and government agencies. Upon completion of this program, graduates will be well-equipped to assume regulatory affairs positions in pharmaceutical, biotechnology, medical device, diagnostic and healthcare products companies, as well as government agencies.
Prof. Karl Wah Keung TSIM
Director of MSc Program in Drug Regulatory Affairs and Policy
Chair Professor, Division of Life Science
Introduction
Master of Science (MSc) in Drug Regulatory Affairs and Policy (DRAP) offering a high-quality MSc program training in the career stream of drug regulatory affairs and policy professionals which is critical for Hong Kong and Greater Bay Area. Establishment of Hong Kong Centre for Medical Products Regulation (CMPR) is one of the highlights in the HKSAR Policy Address 2023. The office will be set up to study the potential restructuring and strengthening of the current regulatory and approval regimes for medicine, medical devices and medical technology to accelerate the approving applications and launching for registration of pharmaceutical products to the market. Our program is unique for preparing students to become top managers and main practitioners of the guidance documents, laws, and regulations for pharmaceutical companies and/or government agencies. With this training and exposure, graduates from the program will be able to manage regulatory affairs positions at pharmaceutical, biotechnology, medical device, diagnostic and healthcare products companies, and government agencies in the careers.
Prof. Karl Wah Keung TSIM
Director of MSc Program in Drug Regulatory Affairs and Policy
Chair Professor, Division of Life Science